RxDoctor Payments Data

Donald McMahon, MD

Family Medicine · Indianapolis, INNPI 1679555718

Payments from drug & device makers

$1,001in general payments, 2019–2025

Across 68 payments — averaging $14.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$240
  • Lilly USA, LLC$122
  • AbbVie$115
  • Novo Nordisk$105
  • Takeda Pharmaceuticals U.S.A., Inc.$83
  • Boehringer Ingelheim$71
  • plus $265 from 9 others

What the payments were for

  • Food & beverage$98298%
  • Education$202%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,001 in reported general payments places this provider in the 60th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$53,256
Medicare patients
162
Services billed
1,042

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide84$102,461
Trelegy ElliptaFluticasone/Umeclidin/Vilanter91$95,987
OzempicSemaglutide53$74,053
JardianceEmpagliflozin70$70,250
EliquisApixaban44$49,673
OxycontinOxycodone Hcl25$40,216
TrulicityDulaglutide16$37,861
RelistorMethylnaltrexone Bromide13$27,562
TrintellixVortioxetine Hydrobromide16$18,741
FarxigaDapagliflozin Propanediol16$14,546
Breo ElliptaFluticasone/Vilanterol29$13,544
Combivent RespimatIpratropium/Albuterol Sulfate16$11,576
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$10,464
Emgality PenGalcanezumab-Gnlm12$9,500
Dexlansoprazole DrDexlansoprazole11$6,698

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$122$140,322100 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$56$119,996132 claims
Boehringer IngelheimJardiance, Combivent Respimat$71$81,82686 claims
Novo NordiskOzempic$105$74,05353 claims
PfizerEliquis$45$49,67344 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$83$18,74116 claims
AstraZenecaFarxiga$240$14,54616 claims
AbbVieSynthroid$115$2,92426 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →